



US00D770057S

(12) **United States Design Patent** (10) **Patent No.:** **US D770,057 S**
Snider et al. (45) **Date of Patent:** **** Oct. 25, 2016**

(54) **BLOOD TEST KIT**

(71) Applicant: **Critical Care Diagnostics, Inc.**, San Diego, CA (US)

(72) Inventors: **James V. Snider**, San Diego, CA (US); **David Geliebter**, Palm Beach Gardens, FL (US)

(73) Assignee: **Critical Care Diagnostics, Inc.**, San Diego, CA (US)

(**) Term: **14 Years**

(21) Appl. No.: **29/503,093**

(22) Filed: **Sep. 23, 2014**

(30) **Foreign Application Priority Data**

Apr. 14, 2014 (EP) 2447078-2
Apr. 14, 2014 (EP) 2447078-3

(51) **LOC (10) Cl.** **24-02**

(52) **U.S. Cl.**
USPC **D24/223**

(58) **Field of Classification Search**

USPC D24/121, 216, 222-232; D10/78, 81, D10/103; 422/408, 430, 501-504, 68.1, 422/547, 67, 411, 401, 420; 436/163, 164, 436/169; 435/6.16, 91.1, 6.11, 287.1, 435/287.2, 7.1, 7.9; 600/300, 583-584; 356/440, 445
CPC . B01J 19/0046; G01N 31/221; G01N 31/22; G01N 21/8483; G01N 21/6428; G01N 21/07; G01N 21/774; G01N 33/54366; G01N 21/474; G01N 33/76; G01N 21/278; G01N 33/558; B01L 2400/0406; B01L 9/54; B01L 2300/0816; B01L 3/502707; B01L 3/5025; B01L 3/5023

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,728,587 A * 3/1998 Kang G01N 33/54366 422/401
5,939,331 A * 8/1999 Burd G01N 33/54366 435/7.9
6,239,445 B1 * 5/2001 Shaeef G01N 21/8483 356/440
6,267,722 B1 * 7/2001 Anderson G01N 21/474 600/300
D454,398 S * 3/2002 Robertson D24/224
D456,082 S * 4/2002 Bouse D24/225
D467,348 S * 12/2002 McMichael D24/223
D468,437 S * 1/2003 McMenamy D24/216
D495,805 S * 9/2004 Lea D24/223

(Continued)

OTHER PUBLICATIONS

Sanada, et al., "IL-33 and ST2 Comprise a Critical Biomechanically Induced and Cardioprotective Signaling System"; The Journal of Clinical Investigation; May 10, 2007.
(Continued)

Primary Examiner — T. Chase Nelson

Assistant Examiner — Mark Cavanna

(74) *Attorney, Agent, or Firm* — Fish & Richardson P.C.

(57) **CLAIM**

The ornamental design for a blood test kit, as shown and described.

DESCRIPTION

FIG. 1 is a front perspective view of a blood test kit showing the new design.

FIG. 2 is a top plan view thereof.

FIG. 3 is a bottom plan view thereof.

FIG. 4 is a left side view thereof.


FIG. 5 is a right side view thereof.

FIG. 6 is a front end side view thereof; and,

FIG. 7 is a back end side view thereof.

The features shown in broken lines in the drawings depict environmental subject matter only and form no part of the claimed design.

1 Claim, 3 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

D500,142 S * 12/2004 Crisanti D24/224
 6,855,561 B2 * 2/2005 Jerome G01N 21/8483
 422/420
 D512,512 S * 12/2005 Bell D24/225
 D531,321 S * 10/2006 Godfrey D24/225
 7,285,425 B2 * 10/2007 Shareef B01L 3/5023
 422/411
 D561,344 S * 2/2008 Kozak D24/216
 7,326,578 B2 * 2/2008 Bateman G01N 33/76
 435/287.1
 D602,599 S * 10/2009 Xiaowei D24/225
 7,847,946 B2 * 12/2010 Krauth G01N 21/278
 356/445
 D639,977 S * 6/2011 Francis D24/225
 D640,389 S * 6/2011 Francis D24/225
 D655,424 S * 3/2012 Castanon D24/225
 D660,977 S * 5/2012 Wagner D24/223

D660,978 S * 5/2012 Wagner D24/223
 8,268,636 B2 * 9/2012 Nazareth G01N 33/558
 422/401
 D668,350 S * 10/2012 Rowley D24/225
 D668,779 S * 10/2012 Khan D24/225
 8,278,109 B2 * 10/2012 Nazareth G01N 33/558
 435/7.1
 D676,570 S * 2/2013 Chance D24/223

OTHER PUBLICATIONS

Sanchez-Mas, et al.; "Modulation of IL-33/ST2 System in Postinfarction Heart Failure: correlation with Cardiac Remodeling Markers"; European Journal of Clinical Investigation; vol. 44; 2014; pp. 643-651.
 Seki, et al., "Interleukin-33 Prevents Apoptosis and Improves survival After Experimental Myocardial Infarction Through ST2 Signaling"; American Heart Association; Feb. 16, 2010.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5



FIG. 6




FIG. 7